Ascentage Pharma announced that it has released the latest results from a Phase Ib/II study of its Bcl-2 inhibitor lisaftoclax in combination with azacitidine in patients with treatment-naïve or relapsed/refractory acute myeloid leukemia, in a poster presentation at the 60th American Society of Clinical Oncology Annual Meeting taking place in Chicago, IL.
